Year: 2019

In the annual survey compiled by the Swedish consultancy, Regi, approximately 250 analysts evaluate Nordic listed companies on 23 different criteria including the quality of quarterly and annual reports, investor presentations, corporate website, top management credibility and overall dialogue with the investors community.Tryg has been ranked ‘best company overall’ both in Denmark and in the Nordics while also Tryg’s IRO (Investor Relations Officer), Gianandrea Roberti, was ranked as the ‘Best IRO’ in Denmark and in the Nordics. Tryg has won both categories for the second year in a row. – “We are very pleased with our very high rankings when it comes to investor relations. It is very important for listed companies to have a good and thorough communication with the research analysts which helps in forming an accurate and detailed...

I den årlige undersøgelse udarbejdet af det svenske konsulenthus, Regi, har mere en 250 analytikere vurderet nordiske børsnoterede selskaber baseret på 23 forskellige parametre inklusive kvaliteten af kvartals- og årsrapporter, investorpræsentationer, hjemmeside, topledelsens troværdighed og overordnet dialog med investorerne.I undersøgelsen blev Tryg kåret som ”best company overall” i både Danmark og Norden, mens Trygs IRO (Investor Relations Officer), Gianandrea Roberti, også blev kåret som ”best IRO” i Danmark og Norden. Det er andet år i træk at Tryg vinder begge kategorier.– ‘Vi er rigtig glade for den flotte placering, når det gælder investor relations. Det er meget vigtigt for børsnoterede selskaber at have en god og indgående dialog med aktieanalytikere, som hjælper med at forme en korrekt og detaljeret forståelse af virksomheden’,...

SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) — Encore Capital Group, Inc. (Nasdaq: ECPG), an international specialty finance company, today announced that Ken Stannard will be stepping down from his role as Executive Director and Chief Executive Officer of its European subsidiary, Cabot Credit Management and, subject to certain regulatory approvals, has appointed Craig Buick as his successor, effective at the end of 2019. “Under Ken’s leadership, Cabot substantially strengthened its market leadership position in the UK and became one of the largest credit management services providers in Europe. In addition, Cabot was the first large credit management services company in the UK to be authorized by the FCA,” said Ashish Masih, Encore’s President and Chief Executive Officer. Stannard joined Marlin Financial Group in 2012 and became Cabot’s...

Maersk Drilling’s Chief Executive Officer, Jorn Madsen, will participate in a panel discussion at the Nordea Bank’s Annual Shipping, Offshore and Energy Seminar in London on Wednesday, 4 December 2019, beginning at 02:35 p.m. GMT.For further information, please contact:Michael Harboe-JørgensenHead of Investor Relations+45 2328 5733Michael.Harboe-Jorgensen@maerskdrilling.comKristoffer ApolloSenior Press Officer+45 2790 3102Kristoffer.Apollo@maerskdrilling.comAttachmentInvestor News – 006 – 26112019 – Nordea Bank’s Annual Shipping, Offshore and Energy Seminar

T4210D — Nov 26 2019 — 1B ToF sensor milestone_IMAGEMilestone demonstrates market leadership in ranging solutionsContinues development of miniature ToF modules that enable innovative use casesMaintains exceptional delivery and quality standards while supplying the most demanding customers in key market sectorsGeneva, November 26, 2019 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, has announced the shipment of its 1 billionth Time-of-Flight (ToF) module.ST’s ToF sensors utilize the Company’s Single Photon Avalanche Diode (SPAD) sensor technology and are manufactured in ST’s 300mm front-end wafer fab in Crolles, France. The final module, which integrates the SPAD sensor, a Vertical Cavity Surface Emission Laser (VCSEL), and the necessary optical...

SummaryThe Board of Directors and Management of FirstFarms A/S have today reviewed and adopted the un-audited interim financial accounts for the period 1 January – 30 September 2019.FirstFarms increases turnover and result significantly based on growth in the pig productionFirstFarms has in the accounting period realised a turnover of DKK 204.0 million compared to DKK 168.4 in the same period in 2018, an EBITDA of DKK 70.0 million and an EBIT of DKK 32.5 million. EBITDA and EBIT are improved with DKK 27.2 million and DKK 11.4 million, respectively compared to the same period last year.The price on piglets and slaughter pigs has been below budget in Q1, 2019 but significantly above in Q2 and Q3, 2019. Together with increased efficiency in production, this has contributed to a satisfactory result for the first 9 months of 2019. Satisfactory...

ResuméBestyrelsen og direktionen i FirstFarms A/S har d.d. behandlet og godkendt det ureviderede delårsregnskab for perioden 1. januar – 30. september 2019.FirstFarms øger omsætning og resultat væsentligt med baggrund i vækst i svineproduktionenPrisen på smågrise og slagtesvin har været under budget i Q1, 2019, men væsentligt over i Q2 og Q3, 2019. Dette har sammen med forøget produktionseffektivitet bidraget til et tilfredsstillende resultat for de første 9 måneder af 2019. Der forventes fortsat tilfredsstillende svinepriser i resten af 2019.Høstudbytterne har været marginalt under budgettet som følge af et meget tørt år; særligt i Rumænien.Mælkeprisen har været lavere end budgetteret. Der forventes en mælkepris på det nuværende niveau for resten af året. Mælkeproduktionen har været på niveau med det budgetterede.Overtagelsen af...

GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASHData Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety dataDSMB guidance remains consistent, supporting favorable safety profile of elafibranorLille (France), Cambridge (Massachusetts, United States), November 26, 2019 – GENFIT (Euronext: GNFT – Nasdaq: GNFT) a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced that the Data Safety Monitoring Board (DSMB) issued a positive recommendation for the continuation, without any modifications, of the RESOLVE-IT Phase 3 trial evaluating elafibranor...

GENFIT : Issue positive du DSMB à 42 mois, recommandant la poursuite de l’étude clinique de Phase 3 RESOLVE-IT évaluant elafibranor dans la NASHLe Data Safety Monitoring Board (DSMB) a recommandé la poursuite de l’essai clinique RESOLVE-IT sans aucune modification, sur base de l’étude planifiée des données de tolérabilité et de sécurité Cette recommandation positive du DSMB est conforme aux observations précédentes confirmant le profil de sécurité favorable d’elafibranor       Lille (France), Cambridge (Massachusetts, États-Unis), le 26 novembre 2019 – GENFIT (Euronext : GNFT – ISIN : FR0004163111), société biopharmaceutique de phase avancée focalisée sur la découverte et le développement de solutions thérapeutiques et diagnostiques innovantes dans le domaine des maladies du foie, notamment d’origine métabolique, a annoncé aujourd’hui...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE STOCK EXCHANGE RELEASE.